
The most lucrative unit of Novo Nordisk's business, Biopharm, has stopped capital from hemorrhaging and is in fact now restored to to growth.
This is not least attributable to hemophilia treatment Novoseven, sales of which have in fact managed to grow during the first six months of this year – a development that can certainly be felt being that the biofarma division accounts for roughly 15 percent of Novo Nordisk's consolidated business.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app